Research programme: junctional adhesion molecule A inhibitors - Pierre Fabre
Alternative Names: 6F4; Anti-JAM-A protein antibodies - Pierre Fabre Centre d’Immunologie; Mab 6F4; Project F50073 - Pierre Fabre Centre d’ImmunologieLatest Information Update: 19 Sep 2023
At a glance
- Originator Pierre Fabre Centre d'Immunologie
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Sep 2023 Discontinued - Preclinical for Cancer in France (Intraperitoneal) (Pierre Fabre Centre d'Immunologie website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in France (Intraperitoneal, Injection)
- 30 Aug 2016 Preclinical trials in Cancer in France (Intraperitoneal) before August 2016 (Pierre Fabre Centre d’Immunologie pipeline, August 2016)